 Baudax Bio, Inc. BXRX, a pharmaceutical company focused on therapeutics for acute care settings, today announced that the Compensation Committee of Baudax Bios Board of Directors approved inducement grants of stock options to purchase an aggregate of 182,187 shares of Baudax Bios common stock and restricted stock units covering 56,384 shares of Baudax Bios common stock to 17 newly-hired employees, with a grant date of March 31, 2020. The equity awards were granted pursuant to the NASDAQ Rule 5635c4 inducement grant exception as a component of each individuals employment compensation and were granted as an inducement material to his or her acceptance of employment with Baudax Bio. The options have an exercise price equal to the closing price of Baudax Bios common stock as reported by NASDAQ on March 31, 2020. 